CD274 and neoplasm: The Kaplan-Meier curves demonstrate that the combination of pembrolizumab with chemotherapy provides a superior long-term survival advantage compared to pembrolizumab alone in patients with tumor PD-L1 expression ranging from 1% to 49% (HR: 0.77, 95%CI: 0.62 to 0.95, P=0.015) (Figure 7).